Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fusen Pharmaceutical Co., Ltd. has announced the acceptance of its application for consistency evaluation of its Nicardipine Hydrochloride Injection by the National Medical Products Administration of China. This development could position Fusen Pharmaceutical as a key player in the market by providing a comprehensive range of specifications for this drug, which is crucial for managing hypertensive emergencies. The approval would align the drug’s quality and efficacy with existing formulations, potentially expanding its market reach and treatment options.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.